Charles A. Brunette

This paper develops a germline polygenic score (PRSagg) to predict prostate cancer aggressiveness and validates it across multiple datasets.

This paper shows the HOXB13 p.G84E variant increases prostate cancer risk by threefold in men, but does not lead to more aggressive cancer.

The paper develops a polygenic risk model for prostate cancer using VA data and validates it in external cohorts, showing its clinical utility in risk stratification.

The paper explores primary care providers' experiences with receiving genetic results from a national biobank study, highlighting challenges in integrating genetic information into routine care.

Population-stratified GWAS of 2,068 traits in 635,969 Million Veteran Program participants, 29% genetically non-European, yields 98,485 associations and 57,601 fine-mapped signals with largely shared cross-population architecture.

The paper describes the design and pilot results of a study returning genetic results for familial hypercholesterolemia to MVP participants, showing a reduction in LDL-C after genetic counseling.

This study surveys primary care physicians on their perceived utility and barriers to using polygenic risk scores for precision preventive care, identifying three subgroups with varying levels of acceptance and concerns.